AeroVironment’s Record Print Ignites Defense; Abivax Rises From the Ashes
A defense-drone blowout and a biotech resurrection lead a quiet, holiday-shortened tape. AeroVironment is up 27% on record revenue; Abivax is up 35% after clearing the safety cloud that crushed it a m
Situational Awareness
🛩️ The defense-drone complex is today’s leadership. AeroVironment’s record print (below) is dragging the whole group higher premarket — Kratos, AEVEX, Unusual Machines, Red Cat, Ondas all bid in sympathy. When the sector leader gaps +27% on a blowout, the cohort gets repriced with it.
📉 Quiet, holiday-shortened week with one big data point. Thursday’s June jobs report is the macro event — consensus is for ~110K nonfarm payrolls, well below May’s 172K. Markets are coming off a record Monday (Dow’s first close above 52,000). The 10-year sits near 4.38%.
🌍 Iran ceasefire is the wildcard. The US said hostilities are paused, but weekend skirmishes leave the truce fragile — the one headline that could flip risk appetite intraday.
🩹 Correction from our prior briefings: we flagged Viridian’s (VRDN) veligrotug as “a binary FDA decision due 6/30.” That decision had already landed — the FDA approved it (as Lumvoa) on June 26, ahead of the PDUFA date. The catalyst resolved positive last week; there is no pending binary today. Apologies for the stale framing.
Top Calls
AVAV +27% · fresh-EP · STRONG⭐⭐⭐ (95) · High — record Q4 revenue $641.6M (+133% YoY), EPS $1.84 (+25% beat), $2.7B bookings / 1.4 book-to-bill, on rVol 11x = institutional-scale accumulation. The cleanest mechanical setup on the board.
ABVX +35% · clinical (Phase 3 + safety) · High — Abivax’s obefazimod hit on Phase 3 maintenance data AND cleared the cancer-safety scare that crashed it −44% on June 2; rVol 10.3x. The biggest gap on the tape.
KTOS / AVEX / UMAC / RCAT +5–11% · sector sympathy · Med — defense-drone basket riding AeroVironment’s coattails; no individual prints, the move is cohort repricing.
ENPH / SEDG / NXT +6–9% · theme · Low–Med — solar bid on the Section 25D residential-credit pull-forward + SolarEdge’s AI-datacenter-power pivot; a sector theme, not a single catalyst.
⚠ No governance SKIPs today — none of today’s movers are on the blacklist (QUBT / PACS HARD-EXCLUDE, SMCI CAUTION all absent).
The Setups
AVAV — a record print the market is treating as a re-rating
AeroVironment reported fiscal Q4 record revenue of $641.6M (+133% YoY) and full-year revenue of $1.977B (+141%), with non-GAAP EPS of $1.84, 25% above consensus, $2.7B of bookings, a 1.4 book-to-bill and a $1.2B funded backlog. The print earned a STRONG⭐⭐⭐ (EP-γ 95) on a maxed-out gap-and-volume profile — +27% premarket on 11x relative volume. One honest caveat in the fine print: FY27 revenue guidance is roughly in-line ($2.13–2.23B), but the FY27 adjusted EPS guide of $3.02–3.34 sits below the ~$3.98 consensus — a margin/spend signal worth noting. The market is looking past it, paying up for the revenue inflection, the backlog, and CEO commentary that the “next big opportunity goes beyond building drones” into autonomous systems and software. What the +27% on 11x volume reflects is institutions repricing a defense-autonomy platform, not a one-quarter pop.
ABVX — back from a near-death drop
Abivax surged ~35% premarket after two things happened at once. First, positive Phase 3 ABTECT Maintenance Part 2 data for obefazimod in moderate-to-severe ulcerative colitis: 37.2% of induction non-responders reached remission at Week 44, and raising the dose to 50mg recaptured remission in 45.5% of relapsers — evidence the drug works in the harder-to-treat refractory population. Second, and arguably more important for the stock, the update defused the safety scare that vaporized 44% of the company’s value on June 2: expanded analysis shows malignancy rates in line with the UC background population. With the NDA planned for Q4 2026, what the move reflects is the market rebuilding a benefit-risk case it had written off a month ago. This is a volatile clinical name — the catalyst is data, not an approval.
Bottom line
Highest-conviction setup on the board: AVAV — a STRONG⭐⭐⭐ defense print pulling its whole cohort up with it.
Tuesday, June 30, 2026 · As of 9:00 AM ET (6:00 AM PT). Markets open 9:30 AM ET.
Your daily premarket briefing, brought to you by SignalDeck.live.
Not financial advice. SignalDeck publishes research and analysis for informational purposes only. Do your own due diligence.